Recombinant protein mio-hsp, method of its production, injection preparation for muscle mass increase in farm animals, birds and animals of canids, as well as method of using preparation
SUBSTANCE: present invention relates to biotechnology and can be used for increasing muscle mass of farm animals, livestock and canines. Fused protein is obtained, consisting of myostatin, Gli-Ser spacer and glucan binding domain of alpha-glucan binding domain of Streptococcus mutans (Mio-HSP), that is used to produce injection preparation for subcutaneous or intramuscular injections in a dose of 50–200 mcg of said protein per one kg of animal body weight or poultry. For producing recombinant protein is grown cell strain E. coli M15 [rMio-HSP] - producer of recombinant protein myocardial HSP, which is obtained by transformation of cells of E. coli M15 plasmid rMio-HSP M15 containing a nucleotide sequence gene coding myocardial HSP, then bind protein myocardial HSP in paragraph 1 in the cell extracts strain E. coli M15 [rMio-HSP] with alpha-glucan binding sorbent by affine interaction incubation procedure, with further washing from unbound bacterial proteins and separating end product.
EFFECT: invention allows to effectively induce synthesis of specific antibodies to myostatin, inhibit and, consequently, stimulate growth of muscular tissue.
4 cl, 7 tbl, 6 ex
SUBSTANCE: invention is related to a method of fracturing a subterranean formation at downhole temperatures exceeding 160°F, comprising introducing into the formation an aqueous gellable fracturing fluid of pH between 9.5 and 11, comprising a hydratable polymer selected from the group consisting of guars and derivatised guars; a crosslinking agent for crosslinking the hydratable polymer to form a polymer gel; and an enzyme breaker comprising the mannanohydrolase enzyme, wherein the enzyme breaker is coded by the nucleotide sequence which is at least 90% homologous with the nucleotide sequence of SEQ ID NO:2.
EFFECT: downhole fracturing operations may be conducted at the temperatures in excess of 160°F.
19 cl, 7 ex, 8 dwg
FIELD: process engineering.
SUBSTANCE: invention covers the processing of biomass of vegetable origin for use as a fuel. Said biomass comprises lignocelluloses and microorganisms of natural biomass that can convert saccharides to lactic acid or its salts. Proposed method comprises preparation of suspension by dispersion of said biomass in water-based fluid, holding of said suspension under conditions suitable for aerobic decomposition by microorganisms to get the suspension including processed biomass as a dispersed solid phase and extraction of processed biomass from said suspension and biomass extract. Besides, biomass extract is separated into outlet water flow and water concentrate. Invention discloses the method of processed biomass combustion.
EFFECT: biomass with decreased amount of undesirable components.
12 cl, 1 tbl, 4 ex
SUBSTANCE: method comprises growing symbiotic inoculum of kefir fungal inoculum and thermophilic lactic acid bacteria Lactobacillus bulgaricus, Lactobacillus acidophilus and Lactobacillus helveticus (1:0.5:0.5:1) on the nutrient medium based on cottage cheese whey, rye flour and growth components at 30±2°C for 8-10 hours. After receiving the inoculum the biomass is isolated to obtain the liquid bacterial concentrate. In another embodiment for preparation of the inoculum of direct application the resulting liquid bacterial concentrate is mixed with the protective medium and frozen at a temperature not higher than (-20°C). The use of the resulting concentrates is proposed as a biologically active food supplement or the inoculum of direct application for kurunga.
EFFECT: inventions enable to increase the biomass yield and to maintain stability of microflora of the bacterial concentrate during prolonged storage to obtain the biologically active food supplement or the inoculum of direct application.
4 cl, 8 tbl, 3 dwg, 6 ex
SUBSTANCE: purification of pravastatin is carried out from stereoisomer 6-epipravastatin. The culture liquid is centrifuged with a content of 6-epipravastatin 7% by weight of pravastatin for separation of mycelium. The native solution is prepared having pH 6.6. Purification of the native solution is carried out by filtration through a layer of basic alumina with pH 10, having activity corresponding to 8% of moisture. Alumina is taken in an amount of 25:1 relative to the amount of pravastatin in the native solution. Pravastatin is extracted by the organic solvent. Final purification of pravastatin is carried out through obtaining of intermediate ammonium salt using 25% aqueous ammonia solution and subsequent conversion to its sodium salt.
EFFECT: invention enables to carry out purification of pravastatin according to the pharmaceutical requirements to quality.
2 cl, 2 ex
SUBSTANCE: group of inventions relates to biotechnology. Claimed is group of inventions: method of obtaining chemical product and apparatus for obtaining chemical product by claimed method. Microorganisms or culture cells are cultivated in fermentation reservoir. Culture liquid is transferred from fermentation reservoir into reservoir of membrane separation for filtration of culture liquid through separation membrane. Fermentation product is collected from liquid obtained after filtration as chemical product. Reverse discharge of unfiltered culture liquid into fermentation reservoir for combination with culture liquid, which did not pass through membrane separation reservoir, is provided. One part of culture liquid is directed to bypass membrane separation reservoir back into fermentation reservoir. Volume of culture liquid flow is regulated in such a way that manometric pressure of culture liquid from the side of flow outlet into membrane separation reservoir constitutes 1 MPa or less. Apparatus includes fermentation reservoir, membrane separation reservoir, circulation pipeline, which connects fermentation reservoir with membrane separation reservoir, means for transfer of culture liquid, installed into circulation pipeline, bypass pipeline for membrane separation reservoir, means for registration of flow pressure from the side of flow inlet into membrane separation reservoir, means for regulation of flow volume, installed into bypass pipeline.
EFFECT: inventions ensure increased output of end product.
13 cl, 23 dwg, 6 tbl, 11 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: presented group of inventions refers to medicine. What is presented is a method for preventing and treating the diabetes mellitus complications associated with the developing degenerative processes of the nervous tissue, comprising administering a medicine containing a peptide of general formula Pro-Gly-Pro, or a pharmaceutically acceptable salt thereof in effective amounts. There are presented pharmaceutical composition comprising said peptide for the neuroprotective therapy of the complications of diabetes mellitus and the method for preparing it.
EFFECT: group of inventions enables the more effective prevention and treatment of the diabetes mellitus complications associated with the developing degenerative processes of the nervous tissue by the use of the peptide Pro-Gly-Pro, or a pharmaceutically acceptable salt thereof.
9 cl, 2 dwg, 4 tbl, 7 ex
SUBSTANCE: fish roe is homogenised. Fish roe hydrolysis is carried out with a ferment preparation "Collagenase" in presence of an inhibitor for 10-12 hours. Chitosan is added to the produced hydrolysate at the ratio of 0.5-1.0:1.0. Components are mixed.
EFFECT: invention makes it possible to accelerate process of chitosan-nucleic complex production.
1 dwg, 1 tbl, 3 ex
SUBSTANCE: method is proposed to produce a foaming agent. The method includes cultivation of a microorganism in a fermentative medium, the cells of which produce a foaming agent extracellularly. At the same time the fermentative medium contains a defoaming agent, which has opacity temperature. Then the defoaming agent is removed at the temperature of the fermentative medium of at least 10°C higher than the opacity temperature of the defoaming agent.
EFFECT: method makes it possible to simplify removal of a defoaming agent from a fermentative medium.
15 cl, 2 dwg, 6 tbl, 4 ex
FIELD: oil and gas industry.
SUBSTANCE: invention relates to the method to produce oil fuel, in which mixing is carried out and reaction of hydrolysis is done with water containing a ferment, which a hydrocarbon oil product, besides, water containing a ferment, is produced by means of mixing of a natural vegetable ferment, containing, at least lipase, in water. The natural vegetable ferment may additionally contain cellulase. The invention also relates to a device for production of oil fuel.
EFFECT: increased efficiency of fuel, which is stable, and also suppression of hazardous substances formation.
10 cl, 11 dwg, 1 ex
SUBSTANCE: phytoplankton is cultivated in electromagnetic bioaccelerators. Oxygen and biomass, consisting of lipids, hydrocarbons and sugars are obtained. Biomass is oxidised. Thermodynamic energy is obtained. Carbon dioxide and NOx are returned to electromagnetic bioaccelerators.
EFFECT: invention makes it possible to obtain biofuel and reuse CO2 and NOx.
9 cl, 10 dwg
SUBSTANCE: invention relates to biotechnology, specifically to novel hetero-multimeric proteins obtained from modified ubiquitin, and can be used in medicine to treat or diagnose diseases associated with hyperprodution of the extradomain B of fibronectin (ED-B). The protein includes two monomeric ubiquitin links which are differently modified through substitutions of at least 6 amino acids in positions 4, 6, 8, 62, 63, 64, 65 and 66 of SEQ ID NO: 1. In the first monomer link the substitutions include: F4W, K6(H, W or F), Q62N, E64(K, R or H), S65(L, F or W), T66(S or P), and in the second monomer link: K6(T, N, S or Q), L8(Q, T, N or S), Q62(W or F), K63(S, T, N or Q), E64(N, S, T or Q), S65(F or W), T66(E or D).
EFFECT: invention enables to obtain a modified heterodimeric ubiquitin protein, capable of binding with ED-B with high affinity.
28 cl, 18 dwg, 3 tbl, 7 ex
SUBSTANCE: group of inventions relates to field of biotechnology and transplantation medicine and represents peptide with amino acid succession SEQ ID NO: 40. Peptide has ability to regenerate bone tissue and specifically bind with surface of apatite mineral.
EFFECT: peptide is able to be stably immobilised on apatite surface for preservation of useful activity and rendering influence on bone regeneration for long time.
9 cl, 3 dwg, 3 tbl, 4 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to biotechnology. There are presented versions of a humanised anti-CD79b antibody, each of which is characterised by the presence of a light and heavy chain and a set of 6 CDR with a specified amino acid sequence and at least one free cysteine amino acid residue specified in A118C (according to the European Numeration) in the heavy chain and V205C (according to the Kabat numeration) in the light chain. There are disclosed: versions of a conjugate compound of the antibody and a drug preparation, wherein the antibody is bond to the drug preparation through free cysteine; an antibody-based pharmaceutical compound for treating cancer; method for detecting CD79b or cancer cells, as well as a method for inhibiting cell proliferation using the conjugate compound. What is described is a method for producing the conjugate compound.
EFFECT: invention can find further application in the therapy of CD79b-associated cancer diseases, including treating haemopoietic tumours in mammals.
70 cl, 20 tbl, 9 ex, 51 dwg
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to biotechnology, namely to novel IL-17-inhibiting polypeptides, corresponding to fused proteins, to compositions and their application for medicinal purposes. Polypeptide contains amino acid sequence, which is selected from group, consisting of GVTLFVALYD YKAFWPGDLS FHKGEKFQIL RTSDGDWWEA RSLTTGETGY IPSNYVAPVD SIQ (SEQ ID NO: 39), GVTLFVALYD YKAFWPGDIS FHKGEKFQIL RTSDGEWWVA RSLTTGEEGY IPSNYVAPVD SIQ (SEQ ID NO: 57) or GVTLFVALYD YKAFWPGDIS FHKGEKFQIL RTSDGEWWIA RSLTTGEEGY IPSNYVAPVD SIQ (SEQ ID NO: 107); amino acid sequence, which has, at least, 80%, preferably, at least, 90%, more preferably, at least, 95% identity of amino acid sequence with SEQ ID NO: 39, SEQ ID NO:57 or SEQ ID NO: 107; fragment or functional derivative of SEQ ID NO: 39, SEQ ID NO: 57 or SEQ ID NO: 107, obtained due to substitution, addition and/or removal of not more than 5 amino acids.
EFFECT: invention makes it possible to bind IL-17 with high specificity and affinity.
33 cl, 17 dwg, 3 tbl, 12 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: presented group of inventions concerns fused proteins, nucleic acids coding these proteins, an expressing cartridge providing nucleic acid expression, a vector comprising this cartridge, a diagnostic technique for in vitro borreliosis, a kit for this diagnostic technique, which use these proteins, as well as a vaccine composition for preventing borreliosis containing these proteins. The characterised fused proteins contain (i) at least one sequence of DbpA protein of the species Borrelia specified in B. afzelii, B. burgdorferi sensu stricto and B. garinii, and (ii) least one sequence of OspC protein of the species Borrelia specified in B. afzelii, B. burgdorferi sensu stricto and B. garinii.
EFFECT: presented group of inventions enables performing more sensitive and specific analyses related to the presence of certain pathogenic species Borrelia.
11 cl, 8 tbl, 7 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology, specifically to a fused protein containing a variant of rodostomin, and can be used in medicine. An ανβ3 integrin selective polypeptide consisting of an amino acid sequence SEQ ID NO:1 conjugated on the N terminal by a linker amino acid sequence containing a combination of the amino acids glycine and serine with a variant of a human serum albumin (HSA) with SEQ ID NO:4.
EFFECT: invention enables the higher therapeutic effectiveness in the diseases related to ανβ3 integrin.
12 cl, 14 dwg, 2 tbl, 7 ex
SUBSTANCE: inventions relate to chimeric proteins, nucleic acid, coding such a protein, an expression cassette, providing the expression of nucleic acid, a vector, including the expression cassette, a method of diagnostics and a set for diagnostics. The characterised chimeric Borrelia protein includes at least one sequence of an extracellular domain of the VlsE Borrelia protein of the first type, corresponding to a certain strain, and at least one sequence of IR6 area of the VlsE Borrelia protein of the second type or Borrelia of the first type, but corresponding to a strain, different from the strain of the first type, with Borrelia being selected from Borrelia stricto-sensu, Borrelia afzelii and Borrelia garinii.
EFFECT: claimed inventions make it possible to carry out diagnostics of Lyme-borreliosis with an increased specificity and sensitivity.
15 cl, 8 tbl, 7 ex
SUBSTANCE: invention relates to biochemistry, in particular, to novel mutants of streptokinase. Claimed are both mutant streptokinase polypeptides and fusion proteins, possessing streptokinase activity. Claimed streptokinases are included into formulations of pharmaceutical compositions, suitable for treatment of blood circulation diseases, in particular thromboses.
EFFECT: invention makes it possible to obtain more effective mutant polypeptides with streptokinase activity in treatment of blood circulation diseases.
20 cl, 37 tbl, 10 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to field of biochemistry, in particular to single variable domain, aimed against IL-6R, to polypeptide and construction, directed against IL-6R, containing said single variable domain, as well as to methods of obtaining them. Disclosed are nucleic acids, coding said single variable domain, polypeptide and construction, as well as genetic constructions, containing said nucleic acids. Described are host cells and host organisms, containing said nucleic acids. Invention also deals with composition for blocking interaction of IL-6/IL-6R, containing effective quantity of described single variable domain, polypeptide, construction, nucleic acid or genetic construction. Also disclosed is method of prevention and/or treatment of at least one of diseases or disorders, associated with IL-6, IL-6R, complex IL-6/IL-6R and/or signal pathways, in which IL-6, IL-6R or complex IL-6/IL-6R is involved and/or biological functions and reactions, win which IL-6, IL-6R or complex IL-6/IL-6R takes part with application of described single variable domain, polypeptide, construction or composition.
EFFECT: invention makes it possible to block interaction of IL-6/IL-6R effectively with increased affinity and biological activity.
25 cl, 70 dwg, 56 tbl, 61 ex
SUBSTANCE: invention represents a combined recombinant protein of the formula: S-L-R, including SR10, SR13, SR15, SdR10, SdR13 or SdR15, which specifically recognises melanoma cells, where S - streptavidin monomer, L - linker having amino-acid sequence Ser-Arg-Asp-Asp-Asp-Asp-Lys containing a restriction site with enteropeptidase and marked as "d", or amino-acid sequence Ser-Arg-Ala-Gly-Ala,R - melanoma-addressing oligopeptide representing R10 having amino-acid sequence Asp-Gly-Ala-Arg-Tyr-Cys-Arg-Gly-Asp-Cys-Phe-Asp-Gly, or R13 having amino-acid sequence Leu-Ser-Gly-Cys-Arg-Gly-Asp-Cys-Phe-Glu-Glu, or R15 having amino-acid sequence Asp-Gly-Phe-Pro-Gly-Cys-Arg-Gly-Asp-Cys-Ser-Gln-Glu. This invention also describes recombinant plasmid DNAs pSR and pSdR for expression of the specified combined proteins, bacterial strains Escherichia coli MG1655/pSR and MG1655/pSdR, producers of the specified combined proteins and a producing method of melanoma-addressing oligopeptide R from combined recombinant proteins SdR10, SdR13 or SdR15.
EFFECT: invention allows producing combined proteins that provide selective and effective binding to receptors on the surface of melanoma cells and can be used in diagnostics and therapy of cancer of a human being.
9 cl, 7 dwg, 5 ex
SUBSTANCE: physiologically active protein or polypeptide are fused with version of alpha-1-antitrypsin, which has at least one mutated aminoacid residue. Mutations are performed in the following positions: asparagine residue instead of proline residue in position 357; or asparagine residue instead of proline residue in position 357 and threonine residue instead of serine in position 359; or asparagine residue instead of proline residue in position 357 and serine residue instead of cysteine in position 232; or asparagine residue instead of proline residue in position 357, threonine residue instead of serine in position 359 and serine residue instead of cysteine in position 232.
EFFECT: invention allows increasing half lifetime of physiologically active protein or polypeptide in vivo by maintaining its stable circulation in blood.
7 cl, 13 dwg, 7 ex